Efficacy of mucus regulation therapy in acute sinusitis
https://doi.org/10.21518/2079-701X-2013-2-24-32
Abstract
Inflammatory diseases of the paranasal sinuses are one of the most actual problems of modern otorhinolaryngology. 15 to 36% of in-patients at ENT units are people suffering from sinusitis. In 2007, the European Academy of Allergology and Clinical Immunology (EAACI) and the European Rhinologic Society (ERS) signed the fundamental document that contains the guidelines for the treatment of rhinosinusitis and nasal polyps - the EPOS (European Position Paper on Rhinosinusitis and Nasal Polyposis). The EPOS relies on a strict evidence-based approach; however, the number of controlled studies of efficacy of drugs, even those with registered indications, was not really big. After treatment experience was accumulated by 2012, the "herbal preparations" group was included in the list of those recommended by the EPOS.
About the Authors
A. I. Kryukov
the Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
A. B. Turovskiy
the Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
G. N. Izotova
the Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
Yu. A. Karyuk
the Moscow Otorhinolaryngology Research and Practical Centre named after L.I. Sverzhevskiy
Russian Federation
Russian Federation
References
1. Марков Г.И. Дифференциальная диагностика и щадящие методы лечения воспалительных заболеваний носа и околоносовых пазух. Автореферат диссертации на соискание ученой степени доктора медицинских наук. – М., 1986. – С. 24.
2. Dorow P., Weiss T., Felix R., Schmutzler H. Effect of a secretolytic and a combination of pinene, limonene and cineole on mucociliary clearance in patients with chronic obstructive pulmonary disease. Arzneimittelforschung 1987; 37 (12): 1378–81.
3. Behrbohm H., Kaschke O., Sydow K. The influence of a secretolytic drug on mucociliary clearance of the maxillary sinus. J Rhinol 1997; 4 (1): 29–33.
4. Roos U., Wulkow R., Wortha HP et al. Freie Radikale in Pathogenese und Therapie von entzündlichen Erkrankungen des Bronchialsystems, in: Meister R, Entzündliche Erkrankungen des Bronchialsystems, Springer Verlag, 1. Auflage 2000, Seiten 1–25.
5. Beuscher N., Kietzmann M., Bien E., Champeroux P. Interference of Myrtol standardised with inflamma-tory and allergic mediators. Arzneim-Forsch/Drug Res 1998; 48 (II), 985–989 et al. A randomised, multi-centered, placebo controlled phase III double blinded study with parallel group comparison to investi-gate the efficacy of Myrtol standardized capsules (4x300 mg oral daily) for patients with acute sinusitis. 92/334. Myrtol standardisiert Dokumentation 1994.
6. Hippeli S. et al. Freie Radikale in Pathogenese und Therapie von entzündlichen Erkrankungen des Bronchialsystems, in: Meister R, Entzündliche Erkrankungen des Bronchialsystems, Springer Verlag, 1. Auflage 2000, Seiten 1–25.
7. Christoph F., Kaulfers P.-M., Stahl-Biskup E. In vitro evaluation of the antibacterial activity of beta-triketones admixed to Melaleuca oils. Planta Med 2001; 67: 768–71.
Review
For citations:
Kryukov AI, Turovskiy AB, Izotova GN, Karyuk YA. Efficacy of mucus regulation therapy in acute sinusitis. Meditsinskiy sovet = Medical Council. 2013;(2):24-32. (In Russ.) https://doi.org/10.21518/2079-701X-2013-2-24-32
Views:
427
Email this article 